BioPharma Resources

NDA 201635 · Supernus Pharms

Trokendi Xr

Topiramate · Oral

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Aug 16, 2013

Approved uses

4

Original approval plus efficacy supplements

Registered trials

302

82 Phase 3, 10 recruiting

FAERS reports

52,165

39,159 serious, 5,671 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

TROKENDI XR is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy TROKENDI XR is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older [see Clinical Studies (14.2) ] . 1.2 Adjunctive Therapy Epilepsy TROKENDI XR is indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 6 years of age and older [see Clinical Studies (14.3) ] . 1.3 Migraine TROKENDI XR is indicated for the preventive treatment of migraine in patients 12 years of age and older [see Clinical Studies (14.4) ] .

Mechanism: The precise mechanisms by which topiramate exerts its anticonvulsant and preventive migraine effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and the preventive treatment of migraine. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • TROKENDI XR · TOPIRAMATE 200MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • TROKENDI XR · TOPIRAMATE 50MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • TROKENDI XR · TOPIRAMATE 100MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
  • TROKENDI XR · TOPIRAMATE 25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Topiramate" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,246
  • off label use5,862
  • headache3,836
  • nausea3,417
  • fatigue3,277
  • migraine2,702
  • product use in unapproved indication2,649
  • pain2,622
  • dizziness2,499
  • seizure2,336
  • diarrhoea2,259
  • condition aggravated2,232

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004139
2005254
2006207
2007196
2008383
2009775
2010941
20111,213
20121,395
20131,215
20141,569
20152,488
20163,070
20172,875
20183,779
20194,340
20203,915
20213,856
20223,667
20233,947
20244,606
20254,491
20262,839

Recalls

4 FDA enforcement reports for this application.

  • Aug 31, 2026 · Class III · Ongoing

    Failed dissolution specifications.

  • Jul 6, 2026 · Class III · Ongoing

    Failed Dissolution Specifications

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Jul 12, 2016 · Class II · Terminated

    Superpotent Drug: Failure of assay specifications in the capsule.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trokendi XR (Topiramate)

2024 spending

$17.9M

Beneficiaries

1,471

9,755 claims

Per beneficiary

$12,185

$31.94 per unit

View as table
YearSpending
2020$57,552,735
2021$60,730,391
2022$60,444,300
2023$32,622,808
2024$17,924,561

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,003 on PubMed

Sponsor: Supernus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.